Literature DB >> 30040226

An In Vitro Model of Hematotoxicity: Differentiation of Bone Marrow-Derived Stem/Progenitor Cells into Hematopoietic Lineages and Evaluation of Lineage-Specific Hematotoxicity.

Prathap Kumar Mahalingaiah1, Tammy Palenski2, Terry R Van Vleet1.   

Abstract

Hematotoxicity is a significant issue for drug safety and can result from direct cytotoxicity toward circulating mature blood cell types as well as targeting of immature blood-forming stem cells/progenitor cells in the bone marrow. In vitro models for understanding and investigating the hematotoxicity potential of new test items/drugs are critical in early preclinical drug development. The traditional method, colony forming unit (CFU) assay, is commonly used and has been validated as a method for hematotoxicity screening. The CFU assay has multiple limitations for its application in investigative work. In this paper, we describe a detailed protocol for a liquid-culture, microplate-based in vitro hematotoxicity assay to evaluate lineage-specific (myeloid, erythroid, and megakaryocytic) hematotoxicity at different stages of differentiation. This assay has multiple advantages over the traditional CFU assay, including being suitable for high-throughput screening and flexible enough to allow inclusion of additional endpoints for mechanistic studies. Therefore, it is an extremely useful tool for scientists in pharmaceutical discovery and development. © 2018 by John Wiley & Sons, Inc.
Copyright © 2018 John Wiley & Sons, Inc.

Entities:  

Keywords:  CD34+ cells; hematopoietic stem/progenitor cells; hematotoxicity; in vitro model

Mesh:

Year:  2018        PMID: 30040226     DOI: 10.1002/cptx.45

Source DB:  PubMed          Journal:  Curr Protoc Toxicol        ISSN: 1934-9254


  1 in total

1.  Metabolite Patterns in Human Myeloid Hematopoiesis Result from Lineage-Dependent Active Metabolic Pathways.

Authors:  Lars Kaiser; Helga Weinschrott; Isabel Quint; Markus Blaess; René Csuk; Manfred Jung; Matthias Kohl; Hans-Peter Deigner
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.